PharmaCielo Ltd. Logo

PharmaCielo Ltd.

PCLOF

(0.8)
Stock Price

0,06 USD

-68.91% ROA

310.46% ROE

-1.67x PER

Market Cap.

18.891.226,98 USD

-371.23% DER

0% Yield

-540.35% NPM

PharmaCielo Ltd. Stock Analysis

PharmaCielo Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PharmaCielo Ltd. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

2 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

Negative ROE (-175.33%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-46.12%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 PBV

The stock's elevated P/BV ratio (6.37x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 DER

The company has a high debt to equity ratio (326%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

PharmaCielo Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PharmaCielo Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

PharmaCielo Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PharmaCielo Ltd. Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 786.901 100%
2020 2.653.917 70.35%
2021 1.944.998 -36.45%
2022 5.308.517 63.36%
2023 1.406.752 -277.36%
2023 1.541.749 8.76%
2024 3.134.720 50.82%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PharmaCielo Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PharmaCielo Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 3.348.210
2016 5.396.302 37.95%
2017 12.804.165 57.86%
2018 118.605 -10695.64%
2019 29.627.946 99.6%
2020 31.210.494 5.07%
2021 17.937.091 -74%
2022 10.703.587 -67.58%
2023 7.100.652 -50.74%
2023 7.812.391 9.11%
2024 7.601.568 -2.77%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PharmaCielo Ltd. EBITDA
Year EBITDA Growth
2015 -4.118.860
2016 -6.653.168 38.09%
2017 -15.980 -41534.34%
2018 -118.605 86.53%
2019 -32.682.424 99.64%
2020 -41.554.719 21.35%
2021 -24.208.237 -71.66%
2022 -9.880.018 -145.02%
2023 -7.527.668 -31.25%
2023 -9.141.720 17.66%
2024 -4.989.040 -83.24%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PharmaCielo Ltd. Gross Profit
Year Gross Profit Growth
2015 -32.736
2016 -68.400 52.14%
2017 -26.874 -154.52%
2018 -653.627 95.89%
2019 -1.659.557 60.61%
2020 -6.799.038 75.59%
2021 -4.308.365 -57.81%
2022 827.059 620.93%
2023 -1.396.748 159.21%
2023 -2.224.070 37.2%
2024 1.259.736 276.55%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PharmaCielo Ltd. Net Profit
Year Net Profit Growth
2015 -4.195.910
2016 -11.261.622 62.74%
2017 -15.982 -70364.41%
2018 -144.395 88.93%
2019 -34.667.341 99.58%
2020 -43.755.809 20.77%
2021 -26.629.693 -64.31%
2022 -14.516.351 -83.45%
2023 -11.042.012 -31.46%
2023 -16.297.635 32.25%
2024 -10.300.608 -58.22%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PharmaCielo Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 -1 100%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PharmaCielo Ltd. Free Cashflow
Year Free Cashflow Growth
2015 -3.035.462
2016 -10.515.603 71.13%
2017 -3.046.126 -245.21%
2018 -4.144.234 26.5%
2019 -35.879.283 88.45%
2020 -27.997.994 -28.15%
2021 -21.211.170 -32%
2022 -10.229.905 -107.34%
2023 -5.165.042 -98.06%
2023 -855.874 -503.48%
2024 -604.988 -41.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PharmaCielo Ltd. Operating Cashflow
Year Operating Cashflow Growth
2015 -2.994.280
2016 -4.042.520 25.93%
2017 -19.912 -20201.93%
2018 -78.469 74.62%
2019 -25.163.629 99.69%
2020 -22.564.214 -11.52%
2021 -20.073.161 -12.41%
2022 -9.708.043 -106.77%
2023 -5.149.774 -88.51%
2023 -855.341 -502.07%
2024 -604.988 -41.38%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PharmaCielo Ltd. Capital Expenditure
Year Capital Expenditure Growth
2015 41.182
2016 6.473.083 99.36%
2017 3.026.214 -113.9%
2018 4.065.765 25.57%
2019 10.715.654 62.06%
2020 5.433.780 -97.2%
2021 1.138.009 -377.48%
2022 521.862 -118.07%
2023 15.268 -3318.01%
2023 533 -2764.54%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PharmaCielo Ltd. Equity
Year Equity Growth
2015 6.437.614
2016 12.470.302 48.38%
2017 91.018 -13600.92%
2018 185.552 50.95%
2019 45.465.301 99.59%
2020 26.246.994 -73.22%
2021 19.325.942 -35.81%
2022 6.391.988 -202.35%
2023 -1.679.628 480.56%
2023 2.785.915 160.29%
2024 -5.425.893 151.34%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PharmaCielo Ltd. Assets
Year Assets Growth
2015 6.619.641
2016 14.620.837 54.72%
2017 103.663 -14004.2%
2018 208.211 50.21%
2019 50.196.362 99.59%
2020 44.024.421 -14.02%
2021 35.956.810 -22.44%
2022 25.115.741 -43.16%
2023 22.289.381 -12.68%
2023 26.641.297 16.34%
2024 20.532.504 -29.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PharmaCielo Ltd. Liabilities
Year Liabilities Growth
2015 182.026
2016 2.150.534 91.54%
2017 12.645 -16906.99%
2018 22.659 44.19%
2019 4.731.061 99.52%
2020 17.777.427 73.39%
2021 16.630.868 -6.89%
2022 18.723.753 11.18%
2023 23.969.009 21.88%
2023 23.855.382 -0.48%
2024 25.958.397 8.1%

PharmaCielo Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.08
Price to Earning Ratio
-1.67x
Price To Sales Ratio
11.66x
POCF Ratio
-6.66
PFCF Ratio
-5.31
Price to Book Ratio
-4.36
EV to Sales
24.08
EV Over EBITDA
-5.66
EV to Operating CashFlow
-10.98
EV to FreeCashFlow
-10.96
Earnings Yield
-0.6
FreeCashFlow Yield
-0.19
Market Cap
0,02 Bil.
Enterprise Value
0,04 Bil.
Graham Number
0.24
Graham NetNet
-0.14

Income Statement Metrics

Net Income per Share
-0.08
Income Quality
0.25
ROE
7.36
Return On Assets
-0.71
Return On Capital Employed
2.18
Net Income per EBT
1
EBT Per Ebit
2.03
Ebit per Revenue
-2.66
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
3.82
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.67
Gross Profit Margin
-0.8
Operating Profit Margin
-2.66
Pretax Profit Margin
-5.4
Net Profit Margin
-5.4

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.65
Return on Tangible Assets
-0.69
Days Sales Outstanding
143.02
Days Payables Outstanding
479.53
Days of Inventory on Hand
177.79
Receivables Turnover
2.55
Payables Turnover
0.76
Inventory Turnover
2.05
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,03
Tangible Book Value per Share
-0.03
Shareholders Equity per Share
-0.03
Interest Debt per Share
0.14
Debt to Equity
-3.71
Debt to Assets
0.98
Net Debt to EBITDA
-2.92
Current Ratio
0.14
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-1301152
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
2174470
Debt to Market Cap
1.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PharmaCielo Ltd. Dividends
Year Dividends Growth

PharmaCielo Ltd. Profile

About PharmaCielo Ltd.

PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.

CEO
Mr. Marc Lustig M.B.A., M.Sc.
Employee
268
Address
82 Richmond Street East
Toronto, M5C 1P1

PharmaCielo Ltd. Executives & BODs

PharmaCielo Ltd. Executives & BODs
# Name Age
1 Mr. Andres Felipe Botero
Chief Operating Officer
70
2 Dr. Decio Rabelo de Castro Filho
Chief Medical Officer
70
3 Mr. Marc Lustig M.B.A., M.Sc.
Chairman & Chief Executive Officer
70
4 Mr. Ian D. Atacan B.Sc., C.M.A., C.P.A., M.B.A.
Chief Financial Officer, Corporate Secretary & Director
70

PharmaCielo Ltd. Competitors